Holen Sie sich die Stockscreener-App
10.30
0.92%
0.1103
Schlusskurs vom Vortag:
$10.19
Offen:
$10.1
24-Stunden-Volumen:
190.99K
Relative Volume:
0.18
Marktkapitalisierung:
$580.15M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-7.9809
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
+14.46%
1M Leistung:
+20.92%
6M Leistung:
+32.62%
1J Leistung:
+29.45%
1-Tages-Spanne:
$10.05
$10.52
1-Wochen-Bereich:
$8.73
$11.40
52-Wochen-Spanne:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(888) 958-1253
Adresse
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
10.30 | 573.39M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.00 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.24 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.00 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.99 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.45 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - simplywall.st
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Zevra Therapeutics appoints Justin Renz as CFO - MSN
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
ZVRA: MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress - TradingView
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge? - Yahoo Finance
Brokers Offer Predictions for ZVRA Q3 Earnings - MarketBeat
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case - simplywall.st
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - TipRanks
Why Is Zevra Therapeutics Stock Trading Higher Today? - Bitget
Why Zevra Therapeutics stock zoomed 21% higher today - MSN
Why Zevra Therapeutics Stock Zoomed 21% Higher Today - Yahoo Finance
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpHere's What Happened - MarketBeat
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA) - Seeking Alpha
GeneDx Holdings Corp. to Launch Genetic Testing Program with Zevra Therapeutics, Inc. to Support Patients with Suspected Niemann-Pick Disease Type C - marketscreener.com
Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S. - Traders Union
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C - Business Wire
Guggenheim raises Zevra Therapeutics stock price target to $23 By Investing.com - Investing.com Australia
US Premarket Movers: BioNTech, Kohl’s, Teladoc, Vertex, Zevra - Bloomberg.com
Guggenheim raises Zevra Therapeutics stock price target to $23 - Investing.com
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim - TipRanks
Zevra Therapeutics Stock Pre-Market (+17%): Blowout Q4 Earnings & Revenue Beat - Trefis
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA) - simplywall.st
Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat - Trefis
Zevra Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Zevra Therapeutics Q4 2025 earnings beat forecasts By Investing.com - Investing.com Australia
ZVRA Stock Soars On Upbeat Q4 Results, Optimism For EMA Approval Of Niemann-Pick Disease Treatment - Asianet Newsable
Earnings call transcript: Zevra Therapeutics Q4 2025 earnings beat forecasts - Investing.com
ZVRA Reports Strong Q4 Revenue and Strategic Growth Plans - GuruFocus
Zevra Therapeutics Q4 Earnings Call Highlights - MarketBeat
Zevra Therapeutics earnings beat by $0.14, revenue topped estimates - Investing.com Canada
Zevra Therapeutics Q4 2025 Earnings: $12.2M Net Income, Revenue Beats ForecastsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Zevra Therapeutics reports Q4 EPS 20c, consensus 5c - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zevra Therapeutics: Fourth Quarter Earnings Overview - Bitget
Zevra 2025 net income hits $83M on $106M revenue - National Today
Zevra Therapeutics Appoints Justin Renz as New CFO - TipRanks
ZVRA Exceeds Revenue Expectations and Expands Boston Headquarters - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Zevra Therapeutics Q4 Swings to Profit, Revenue Rises - marketscreener.com
Zevra Therapeutics beats FY 2025 revenue expectations - TradingView
Zevra Therapeutics Reports Q4 2025 Financial Results with 31% Revenue Growth and Announces Upcoming Conference Call - Quiver Quantitative
Zevra Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Feb 03 '26 |
Sale |
9.18 |
3,000 |
27,548 |
29,590 |
| Schafer Joshua | CCO |
Feb 03 '26 |
Sale |
9.19 |
10,500 |
96,500 |
62,278 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Jan 30 '26 |
Sale |
8.82 |
1,750 |
15,442 |
20,924 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jan 30 '26 |
Sale |
8.83 |
4,080 |
36,010 |
49,919 |
| Quartel Adrian W | Chief Medical Officer |
Jan 30 '26 |
Sale |
8.83 |
4,533 |
40,036 |
9,723 |
| Schafer Joshua | CCO |
Jan 30 '26 |
Sale |
8.83 |
3,375 |
29,800 |
37,444 |
| McFarlane Neil F. | President and CEO |
Feb 02 '26 |
Sale |
9.38 |
91,000 |
853,425 |
364,350 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):